Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Richard H, Scarpignato, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816037/
https://www.ncbi.nlm.nih.gov/pubmed/26513137
http://dx.doi.org/10.1038/ctg.2015.39
_version_ 1782424657129897984
author Hunt, Richard H
Scarpignato, Carmelo
author_facet Hunt, Richard H
Scarpignato, Carmelo
author_sort Hunt, Richard H
collection PubMed
description The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental advance in control of acid secretion over the delayed-release proton pump inhibitors. Vonoprazan (a new potassium-competitive acid blocker) displays more potent and extended 24 h acid suppression and preliminary Japanese trials translate this into meaningful clinical benefits in gastro-esophageal reflux disease and Helicobacter pylori eradication. We review the vonoprazan information to date and the indications, benefits, and concerns of more effective therapeutic control of acid secretion.
format Online
Article
Text
id pubmed-4816037
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48160372016-04-13 Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease? Hunt, Richard H Scarpignato, Carmelo Clin Transl Gastroenterol Editorial The need for new acid suppressing agents with improved pharmacology and superior antisecretory effects to address unmet clinical needs in acid-related disorders has been evident for over a decade. Recent new antisecretory drugs (IR-omeprazole and MR-dexlansoprazole) only provide a small incremental advance in control of acid secretion over the delayed-release proton pump inhibitors. Vonoprazan (a new potassium-competitive acid blocker) displays more potent and extended 24 h acid suppression and preliminary Japanese trials translate this into meaningful clinical benefits in gastro-esophageal reflux disease and Helicobacter pylori eradication. We review the vonoprazan information to date and the indications, benefits, and concerns of more effective therapeutic control of acid secretion. Nature Publishing Group 2015-10 2015-10-29 /pmc/articles/PMC4816037/ /pubmed/26513137 http://dx.doi.org/10.1038/ctg.2015.39 Text en Copyright © 2015 American College of Gastroenterology http://creativecommons.org/licenses/by-nc-nd/4.0/ Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Editorial
Hunt, Richard H
Scarpignato, Carmelo
Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title_full Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title_fullStr Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title_full_unstemmed Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title_short Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
title_sort potassium-competitive acid blockers (p-cabs): are they finally ready for prime time in acid-related disease?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816037/
https://www.ncbi.nlm.nih.gov/pubmed/26513137
http://dx.doi.org/10.1038/ctg.2015.39
work_keys_str_mv AT huntrichardh potassiumcompetitiveacidblockerspcabsaretheyfinallyreadyforprimetimeinacidrelateddisease
AT scarpignatocarmelo potassiumcompetitiveacidblockerspcabsaretheyfinallyreadyforprimetimeinacidrelateddisease

Ejemplares similares